IOM On “Omics” Assays: Stricter Controls Are Needed For Development Process
This article was originally published in The Gray Sheet
The Institute of Medicine recommends a highly controlled, step-wise approach to bringing complex genomic, proteomic and similar assays from basic research to clinical testing. FDA needs to play a central role, IOM stresses in a recent report.
You may also be interested in...
Although FDA is still developing its lab-developed test regulatory framework, it has agreed not to collect user fees to support its planned review of the tests.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.